UA96575C2 - Process for the preparation of olmesartan medoxomil - Google Patents
Process for the preparation of olmesartan medoxomilInfo
- Publication number
- UA96575C2 UA96575C2 UAA200801032A UAA200801032A UA96575C2 UA 96575 C2 UA96575 C2 UA 96575C2 UA A200801032 A UAA200801032 A UA A200801032A UA A200801032 A UAA200801032 A UA A200801032A UA 96575 C2 UA96575 C2 UA 96575C2
- Authority
- UA
- Ukraine
- Prior art keywords
- preparation
- olmesartan medoxomil
- olmesartan
- hypertension
- medicament
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to an improved process for the manufacture of olmesartan and pharmaceutically acceptable salts and esters thereof as an active ingredient of a medicament for the treatment of hypertension and related diseases and conditions.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200500221A SI22092A (en) | 2005-07-29 | 2005-07-29 | Procedure for preparation of olmertsan medoximil |
Publications (1)
Publication Number | Publication Date |
---|---|
UA96575C2 true UA96575C2 (en) | 2011-11-25 |
Family
ID=37774952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200801032A UA96575C2 (en) | 2005-07-29 | 2006-07-27 | Process for the preparation of olmesartan medoxomil |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101238119A (en) |
SI (1) | SI22092A (en) |
UA (1) | UA96575C2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009151016A1 (en) | 2008-06-09 | 2009-12-17 | 第一三共株式会社 | Method for producing 1-biphenylmethylimidazole compound |
KR20120006513A (en) | 2009-04-28 | 2012-01-18 | 다이이찌 산쿄 가부시키가이샤 | Novel solvate crystals |
CN102414200B (en) | 2009-04-28 | 2014-12-17 | 第一三共株式会社 | Method for producing olmesartan medoxomil |
CN102050816A (en) * | 2009-10-28 | 2011-05-11 | 北京万全阳光医学技术有限公司 | Method for synthesizing olmesartan medoxomil |
CN102206208A (en) * | 2010-12-24 | 2011-10-05 | 上海现代制药股份有限公司 | Preparation method for olmensartan medoxomil with low-level impurity |
CN102558161B (en) * | 2011-12-07 | 2016-07-06 | 浙江华海药业股份有限公司 | A kind of technique adopting the refining olmesartan medoxomil of acetone and water mixed liquid |
CN103880825B (en) * | 2014-03-14 | 2019-03-05 | 浙江华海药业股份有限公司 | A kind of preparation process of high-purity trityl olmesartan medoxomil |
CN104447715B (en) * | 2014-11-28 | 2017-06-20 | 山东新华制药股份有限公司 | The preparation method of olmesartan medoxomil |
CN107311990B (en) * | 2017-07-25 | 2021-09-03 | 浙江华海致诚药业有限公司 | Preparation method of olmesartan medoxomil |
CN109761966A (en) * | 2019-01-30 | 2019-05-17 | 浙江省食品药品检验研究院 | A kind of Olmesartan medoxomil crystal and preparation method thereof |
CN112321575B (en) * | 2020-11-18 | 2023-07-21 | 福建天泉药业股份有限公司 | Olmesartan medoxomil refining method suitable for industrial production |
CN115887393B (en) * | 2022-10-31 | 2024-05-24 | 修正药业集团股份有限公司 | Olmesartan medoxomil tablet and preparation method thereof |
-
2005
- 2005-07-29 SI SI200500221A patent/SI22092A/en not_active IP Right Cessation
-
2006
- 2006-07-27 UA UAA200801032A patent/UA96575C2/en unknown
- 2006-07-27 CN CNA2006800277643A patent/CN101238119A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101238119A (en) | 2008-08-06 |
SI22092A (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007017135A3 (en) | Process for the preparation of olmesartan medoxomil | |
UA96575C2 (en) | Process for the preparation of olmesartan medoxomil | |
WO2007003330A3 (en) | Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist | |
AR047993A1 (en) | PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES | |
IN2012DN02465A (en) | ||
UA90545C2 (en) | Solid orally administerable pharmaceutical dosage forms with rapid release of inhibitor of coagulation factor xa | |
AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
UA110013C2 (en) | APPLICATION OF THE COMPOSITION FOR THE TREATMENT OF BALL-MARI-HERE AND THE RELATED DISORDERS | |
MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
NZ589764A (en) | NMDA receptor antagonists for the treatment of neuropsychiatric disorders | |
WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
MX2009006764A (en) | Bicyclic pyrimidinones and uses thereof. | |
WO2009109616A8 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2011023367A3 (en) | Bisphosphonate-prodrugs | |
NZ597866A (en) | Therapeutic lactams | |
MX2009007040A (en) | Isosorbide mononitrate derivatives for the treatment of ocular hypertension. | |
SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
UA95274C2 (en) | Solid pharmaceutical composition comprising irbesartan and processes for the manufacture thereof | |
WO2007134085A3 (en) | Isothiazolidines useful in the treatment of ocular hypertensive conditions | |
NO20082140L (en) | Process for making candesartan lexile | |
WO2010048452A3 (en) | Polycyclic compounds and methods related thereto | |
SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
WO2010013925A3 (en) | Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof |